Een first-in-mens onderzoek van KK2223 bij deelnemers met recidiverende of refractaire T-cel Non-Hodgkin-lymfoom
Een fase 1, multicenter, open-label, niet-gerandomiseerde, dosis-escalatie- en opvulstudie van KK2223 bij deelnemers met recidiverende of refractaire T-cel niet Hodgkin-lymfoom
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Studie Overzicht
Gedetailleerde beschrijving
This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Kyowa Kirin, Inc.
- Telefoonnummer: +1-609-919-1100
- E-mail: KKD.Clinical.82@kyowakirin.com
Studie Locaties
-
-
-
Bergamo, Italië, 24127
- Nog niet aan het werven
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
-
Hoofdonderzoeker:
- Giuseppe Gritti
-
Contact:
- Giuseppe Gritti
- Telefoonnummer: 39035269492
- E-mail: giuseppe_gritti@yahoo.it
-
Bologna, Italië, 40138
- Nog niet aan het werven
- Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
-
Contact:
- Luigi Zinzani Pier
- Telefoonnummer: 390516363680
- E-mail: pierluigi.zinzani@unibo.it
-
Hoofdonderzoeker:
- Luigi Zinzani Pier
-
Torino, Italië, 10126
- Nog niet aan het werven
- AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
-
Contact:
- Federica Cavallo
- Telefoonnummer: 390116334264
- E-mail: f.cavallo@unito.it
-
Hoofdonderzoeker:
- Federica Cavallo
-
-
Torino
-
Candiolo, Torino, Italië, 10060
- Nog niet aan het werven
- Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
-
Hoofdonderzoeker:
- Umberto Vitolo
-
Contact:
- Umberto Vitolo
- Telefoonnummer: 390116335934
- E-mail: umberto.vitolo@ircc.it
-
-
-
-
-
Madrid, Spanje, 28027
- Nog niet aan het werven
- Clinica Universidad de Navarra - Hematología y Hemoterapia
-
Contact:
- Miguel Canales Albendea
- Telefoonnummer: 34917277116
- E-mail: macanales@unav.es
-
Hoofdonderzoeker:
- Migue Canales Albendea
-
-
Barcelona
-
Badalona, Barcelona, Spanje, 8036
- Nog niet aan het werven
- Hospital Clinic De Barcelona - Hematología
-
Hoofdonderzoeker:
- Pablo Mozas
-
Contact:
- Pablo Mozas
- Telefoonnummer: 34 93 227 22 71
- E-mail: mozas@clinic.cat
-
L'Hospitalet de Llobregat, Barcelona, Spanje, 8907
- Nog niet aan het werven
- Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
-
Hoofdonderzoeker:
- Eva Domingo Domenech
-
Contact:
- Eva Domingo Domenech
- Telefoonnummer: 34932607822
- E-mail: edomingo@iconcologia.net
-
-
Navarre
-
Pamplona, Navarre, Spanje, 31008
- Nog niet aan het werven
- Clinica Universidad de Navarra - Hematología
-
Contact:
- Miguel Canales Albendea
- Telefoonnummer: 34917277116
- E-mail: macanales@unav.es
-
Hoofdonderzoeker:
- Miguel Canales Albendea
-
-
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- Nog niet aan het werven
- City of Hope
-
Hoofdonderzoeker:
- Christina Poh
-
Contact:
- Christina Poh
- Telefoonnummer: 916-734-7131
- E-mail: cpoh@coh.org
-
Orange, California, Verenigde Staten, 92868
- Nog niet aan het werven
- University of California, Irvine Medical Center - Hematology/Oncology
-
Contact:
- Lauren Pinter Brown
- Telefoonnummer: 7144568200
- E-mail: lpinterb@uci.edu
-
Hoofdonderzoeker:
- Lauren Pinter Brown
-
Stanford, California, Verenigde Staten, 94305
- Werving
- Stanford University School of Medicine
-
Hoofdonderzoeker:
- Youn Kim
-
Contact:
- Youn Kim
- Telefoonnummer: 650-723-7893
- E-mail: younkim@stanford.edu
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- Nog niet aan het werven
- Moffit Cancer Center
-
Contact:
- Yumeng Zhang
- Telefoonnummer: 844-304-8636
- E-mail: yumeng.zhang@moffitt.org
-
Hoofdonderzoeker:
- Yumeng Zhang
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Nog niet aan het werven
- Emory University Medical Center
-
Hoofdonderzoeker:
- Pamela Allen
-
Contact:
- Pamela Allen
- Telefoonnummer: 404-778-2407
- E-mail: pallen5@emory.edu
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- Nog niet aan het werven
- University of Iowa Health
-
Hoofdonderzoeker:
- Eric Mou
-
Contact:
- Eric Mou
- Telefoonnummer: 800-777-8442
- E-mail: eric-mou@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Nog niet aan het werven
- Beth Israel Deaconess Medical Center - Research
-
Contact:
- Salvia Jain
- Telefoonnummer: 617-726-2000
- E-mail: salvia.jain@mgh.harvard.edu
-
Hoofdonderzoeker:
- Salvia Jain
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Washington University School of Medicine - Oncology Hospital - Public
-
Hoofdonderzoeker:
- Neha Mehta Shah
-
Contact:
- Neha Mehta Shah
- Telefoonnummer: 314.273-8566
- E-mail: mehta-n@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601-2105
- Nog niet aan het werven
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
-
Hoofdonderzoeker:
- Tatyana Feldman
-
Contact:
- Tatyana Feldman
- Telefoonnummer: 551-996-5900
- E-mail: tatyana.feldman@hmhn.org
-
-
New York
-
New York, New York, Verenigde Staten, 10021-6007
- Werving
- Memorial Sloan Kettering Cancer Center
-
Hoofdonderzoeker:
- Jasmine Zain
-
Contact:
- Jasmine Zain
- Telefoonnummer: 212-639-3045
- E-mail: zainj1@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Nog niet aan het werven
- University Hospitals Cleveland Medical Center
-
Contact:
- Kevin Cooper
- Telefoonnummer: 216-844-8200
- E-mail: kevin.cooper@uhhospitals.org
-
Hoofdonderzoeker:
- Kevin Cooper
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Nog niet aan het werven
- Oregon Health & Science University
-
Contact:
- Craig Okada
- Telefoonnummer: 503-494-8397
- E-mail: okadac@ohsu.edu
-
Hoofdonderzoeker:
- Craig Okada
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Nog niet aan het werven
- University of Pennsylvania - Abramson Cancer Center
-
Hoofdonderzoeker:
- Stefan Barta
-
Contact:
- Stefan Barta
- Telefoonnummer: 215-728-2674
- E-mail: Stefan.Barta@pennmedicine.upenn.edu
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- The University of Texas - MD Anderson Cancer Center
-
Hoofdonderzoeker:
- Ranjit Nair
-
Contact:
- Ranjit Nair
- Telefoonnummer: 171-379-2860
- E-mail: rnair@mdanderson.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
- PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
- Availability of tumor tissue (current or archival) is required.
- Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
- ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
- Body weight 40 kg to ≤ 200 kg
- Life expectancy ≥3 months.
- Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
- Restrictions on gamete donation and freezing during and after treatment.
- Ability to provide informed consent and comply with study procedures. -
Exclusion Criteria:
- Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
- Pregnant or breastfeeding females, or those intending pregnancy.
- History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
- Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
- Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
- Use of other investigational drugs within 14 days or 5 half-lives before treatment.
- Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
- Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
- Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
- Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
- Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
- Prolonged QT/QTc interval (e.g., QTcF >480 ms).
- Active second primary malignancies except specified non-exclusionary cases.
- CNS involvement.
- Any condition that may impair compliance or study completion as judged by the Investigator.
- Known hypersensitivity to any excipients in the drug formulation.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part One (Dose Escalation)
In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design. |
Intravenous infusion |
|
Experimenteel: Part Two (Backfill)
Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment. |
Intravenous infusion |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tijdsspanne: Through study completion, an average of 1.5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tijdsspanne: Through study completion, an average of 1.5 years
|
Vital signs (mmHg in Systolic/Diastolic blood pressure) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tijdsspanne: Through study completion, an average of 1.5 years
|
Pulse rate (beats/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tijdsspanne: Through study completion, an average of 1.5 years
|
Respiratory Rate (breath/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tijdsspanne: Through study completion, an average of 1.5 years
|
Temperature (°Celcius) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tijdsspanne: Through study completion, an average of 1.5 years
|
ECG parameters (PR interval, QRS interval, QT interval, QTc interval) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tijdsspanne: Through study completion, an average of 1.5 years
|
Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD) |
Through study completion, an average of 1.5 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean Blood Drug Concentration
Tijdsspanne: Through study completion, an average of 1.5 years
|
The mean drug concentration in the blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the immunogenicity of KK2223.
Tijdsspanne: Through study completion, an average of 1.5 years
|
Incidence of Anti drug antibodies (ADA) in blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tijdsspanne: Through study completion, an average of 1.5 years
|
% in Overall Response Rate (ORR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tijdsspanne: Through study completion, an average of 1.5 years
|
% in Compartment Response (if applicable) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tijdsspanne: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Duration of Response (DOR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tijdsspanne: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tijdsspanne: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Response (TTR) |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Tijdsspanne: Through study completion, an average of 1.5 years
|
The maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Tijdsspanne: Through study completion, an average of 1.5 years
|
A measure of the overall drug exposure over time |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Tijdsspanne: Through study completion, an average of 1.5 years
|
The time taken to reach the maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Tijdsspanne: Through study completion, an average of 1.5 years
|
The time required for the drug concentration to decrease by 50% |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Clearance (CL)
Tijdsspanne: Through study completion, an average of 1.5 years
|
Rate of drug elimination from the body |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Tijdsspanne: Through study completion, an average of 1.5 years
|
Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues |
Through study completion, an average of 1.5 years
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Lymfoom, non-Hodgkin
- Lymfoom, T-cel
- Hemische en lymfatische ziekten
- Neoplasmata
- Lymfoom
- Lymfoom, T-cel, perifeer
- Lymfoom, T-cel, huid
- Ziekten van het immuunsysteem
- Mycose Fungoides
- Sezary-syndroom
Andere studie-ID-nummers
- 2223-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .